S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Senate parliamentarian OKs most of Dems' drug price controls
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Senate rules referee weakens Dem drug plan in economic bill
Demand for grocery delivery cools as food costs rise
Venezuela, Colombia border areas hopeful as reopening looms
pixel
NYSE:ABBV

AbbVie (ABBV) Stock Forecast, Price & News

$138.04
-0.88 (-0.63%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$137.95
$139.91
50-Day Range
$137.62
$154.14
52-Week Range
$105.56
$175.91
Volume
5.37 million shs
Average Volume
6.05 million shs
Market Capitalization
$243.93 billion
P/E Ratio
19.55
Dividend Yield
4.09%
Price Target
$159.29

AbbVie MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
16.3% Upside
$160.50 Price Target
Short Interest
Healthy
0.80% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.23mentions of AbbVie in the last 14 days
Based on 47 Articles This Week
Insider Trading
Selling Shares
$55.53 M Sold Last Quarter
Proj. Earnings Growth
-16.01%
From $14.05 to $11.80 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

79th out of 1,283 stocks

Pharmaceutical Preparations Industry

26th out of 615 stocks

AbbVie logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Stock Performance

NYSE:ABBV traded down $0.88 during trading on Friday, hitting $138.04. The company's stock had a trading volume of 5,371,137 shares, compared to its average volume of 6,052,852. AbbVie has a 52 week low of $105.56 and a 52 week high of $175.91. The firm has a market cap of $243.93 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 3.90 and a beta of 0.70. The firm has a 50 day moving average price of $147.52 and a 200 day moving average price of $150.16. The company has a quick ratio of 0.71, a current ratio of 0.82 and a debt-to-equity ratio of 3.89.

AbbVie (NYSE:ABBV - Get Rating) last released its earnings results on Friday, July 29th. The company reported $3.37 EPS for the quarter, beating the consensus estimate of $3.31 by $0.06. The firm had revenue of $14.58 billion during the quarter, compared to analysts' expectations of $14.64 billion. AbbVie had a net margin of 22.03% and a return on equity of 157.31%. The business's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.11 EPS. Equities research analysts forecast that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Friday, July 15th will be issued a $1.41 dividend. The ex-dividend date of this dividend is Thursday, July 14th. This represents a $5.64 annualized dividend and a yield of 4.09%. AbbVie's dividend payout ratio (DPR) is 79.89%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on AbbVie from $122.00 to $140.00 and gave the stock a "neutral" rating in a report on Tuesday, April 12th. UBS Group reduced their price target on AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Piper Sandler dropped their price objective on AbbVie from $160.00 to $155.00 in a report on Friday, July 29th. Barclays lifted their target price on shares of AbbVie from $150.00 to $174.00 and gave the company an "equal weight" rating in a research note on Tuesday, April 12th. Finally, Wells Fargo & Company increased their price target on shares of AbbVie from $165.00 to $200.00 in a research note on Monday, May 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and an average target price of $160.50.

Insiders Place Their Bets

In other AbbVie news, Vice Chairman Michael Severino sold 79,801 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total value of $12,041,970.90. Following the sale, the insider now owns 152,103 shares of the company's stock, valued at approximately $22,952,342.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the completion of the transaction, the executive vice president now directly owns 16,623 shares in the company, valued at $2,576,565. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Vice Chairman Michael Severino sold 79,801 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the completion of the sale, the insider now owns 152,103 shares in the company, valued at approximately $22,952,342.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 363,761 shares of company stock worth $55,528,771. 0.08% of the stock is currently owned by company insiders.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

3 Pharma Stocks' Post-Earnings Price Moves
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
MarketBeat: Week in Review 7/25 – 7/29 (ABBV)
The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week.
Here's Bill Bonner's "4th and Final Prediction"
One of America's most successful entrepreneurs goes public with "4th and Final Prediction." His first three all came true—will this one too?
Should You Buy AbbVie Ahead Of Earnings?
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
MarketBeat: Week in Review 7/18 – 7/22 (ABBV)
Investors should be careful not to read too much into this week's rally. Next week will bring the Fed's decision on interest rates and key earnings reports from the tech sector. Both could cause significant movement in either direction. While you wait, here are some of the stocks our analysts were looking at this week
A Dose of AbbVie Stock Can Help Your Bear Market Portfolio
AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that’s exactly why it makes sense to add or hold in your bear market portfolio.
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
What's Happening With AbbVie Stock?
AbbVie (NYSE:ABBV) Given New $160.00 Price Target at Barclays
AbbVie (NYSE:ABBV) PT Lowered to $188.00 at Morgan Stanley
What’s Happening With AbbVie Stock?
AbbVie (NYSE:ABBV) Given New $146.00 Price Target at UBS Group
See More Headlines

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 5/16 Dividend
4/13/2022
Dividend Payable
5/16/2022
Ex-Dividend for 8/15 Dividend
7/14/2022
Last Earnings
7/29/2022
Today
8/07/2022
Dividend Payable
8/15/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$160.50
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+15.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
16 Analysts

Profitability

Net Income
$11.54 billion
Pretax Margin
24.54%

Debt

Sales & Book Value

Annual Sales
$56.20 billion
Cash Flow
$17.67 per share
Book Value
$8.73 per share

Miscellaneous

Outstanding Shares
1,767,110,000
Free Float
1,765,696,000
Market Cap
$243.93 billion
Optionable
Optionable
Beta
0.70

Social Links















ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie
or view top-rated stocks.

What is AbbVie's stock price forecast for 2022?

16 Wall Street research analysts have issued 1-year price targets for AbbVie's stock. Their ABBV stock forecasts range from $135.00 to $200.00. On average, they predict AbbVie's stock price to reach $160.50 in the next twelve months. This suggests a possible upside of 16.3% from the stock's current price.
View analysts' price targets for AbbVie
or view top-rated stocks among Wall Street analysts.

How has AbbVie's stock price performed in 2022?

AbbVie's stock was trading at $135.40 at the beginning of the year. Since then, ABBV stock has increased by 1.9% and is now trading at $138.04.
View the best growth stocks for 2022 here
.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) issued its quarterly earnings data on Friday, July, 29th. The company reported $3.37 EPS for the quarter, beating analysts' consensus estimates of $3.31 by $0.06. The business had revenue of $14.58 billion for the quarter, compared to analysts' expectations of $14.64 billion. AbbVie had a trailing twelve-month return on equity of 157.31% and a net margin of 22.03%. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.11 EPS.
Read AbbVie's conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, June 23rd. Investors of record on Friday, July 15th will be paid a dividend of $1.41 per share on Monday, August 15th. This represents a $5.64 dividend on an annualized basis and a yield of 4.09%. The ex-dividend date is Thursday, July 14th.
View AbbVie's dividend history
.

Is AbbVie a good dividend stock?

AbbVie(NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 4.09%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 79.89%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.80% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its second quarter 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of $3.24-$3.28 for the period, compared to the consensus EPS estimate of $3.43. The company issued revenue guidance of -.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

What other stocks do shareholders of AbbVie own?

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.30%), Envestnet Asset Management Inc. (0.19%), Truist Financial Corp (0.18%), abrdn plc (0.17%), DekaBank Deutsche Girozentrale (0.16%) and Thornburg Investment Management Inc. (0.15%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends for AbbVie
.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $138.04.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $243.93 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.06 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More

When was AbbVie founded?

AbbVie was founded in 2013.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for AbbVie is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.